AtaiBeckley (ATAI) has announced plans to initiate a Phase 3 clinical trial for its investigational depression therapy following a successful pre-Phase 3 meeting with the U.S. Food and Drug Administration. The move marks a critical advancement in the company’s development pipeline and could influence its market trajectory.
- Phase 3 trial for ATAI-101 to enroll 650 patients with MDD across North America and Europe.
- Primary endpoint: change in MADRS scores after 8 weeks of treatment.
- FDA confirmed trial design and biomarker strategy meet regulatory standards.
- Topline results expected by early 2028.
- ATAI stock rose 18% post-announcement in after-hours trading.
- Related healthcare ETFs XLV and IPOE saw increased investor attention.
AtaiBeckley (ATAI) has confirmed it will begin a global Phase 3 clinical trial for its novel depression treatment, designated ATAI-101, after receiving a positive response from the FDA during a pre-Phase 3 meeting. The trial is designed to evaluate the drug’s efficacy and safety in approximately 650 adult patients with moderate to severe major depressive disorder (MDD), with a primary endpoint focused on change in MADRS (Montgomery-Åsberg Depression Rating Scale) scores after eight weeks of treatment. The FDA’s feedback validated the proposed trial design, including the use of a placebo-controlled, double-blind, randomized approach across multiple sites in North America and Europe. The agency also affirmed that the company’s proposed biomarker strategy and patient selection criteria meet regulatory standards, enabling a streamlined path toward potential approval. The Phase 3 study is expected to enroll patients starting in Q3 2026, with topline results anticipated by early 2028. This milestone follows a series of positive Phase 2 data readouts in 2025, where ATAI-101 demonstrated statistically significant improvement in depressive symptoms compared to placebo, with a 58% response rate observed in the high-dose group. The announcement triggered immediate market interest, with ATAI’s stock surging 18% in after-hours trading. Investors have also shown increased activity in related healthcare ETFs such as XLV and IPOE, reflecting broader optimism in the mental health therapeutics segment. The trial’s progress positions ATAI as a key player in the next generation of psychiatric drug development.